Pharmacogenomic Study (Adjuvant Chemotherapy)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01470404|
Recruitment Status : Completed
First Posted : November 11, 2011
Last Update Posted : January 17, 2018
To assess the role of germline polymorphisms in xenobiotic metabolism genes in toxicity profile.
To assess the role of germline polymorphisms in genes associated with DNA repair, p53 tumor suppressor gene and angiogenesis pathway in predicting recurrence and survival in gastric cancer patients treated with adjuvant chemotherapy.
|Condition or disease|
|Study Type :||Observational|
|Actual Enrollment :||792 participants|
|Official Title:||Pharmacogenomic Study to Predict Toxicity and Response in Gastric Cancer Patients Treated With Adjuvant Chemotherapy|
|Actual Study Start Date :||July 10, 2008|
|Actual Primary Completion Date :||May 10, 2013|
|Actual Study Completion Date :||July 10, 2013|
Patients enrolled on to the adjuvant XP trial + patients who received adjuvant chemotherapy following curative resection of gastric cancer
- germline polymorphisms in xenobiotic metabolism genes in toxicity profile [ Time Frame: 36 months ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01470404
|Korea, Republic of|
|Samsung Medical Center|
|Seoul, Korea, Republic of|
|Principal Investigator:||won ki kang, MD||Samsung Medical Center|